By Connor Hart
Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body produces too much cortisol.
The Redwood City, Calif., company said Monday its application is based on positive results observed in patients receiving the treatment, relacorilant, in both recent and continuing trials.
"Patients in these studies who received relacorilant experienced improvements in a wide array of hypercortisolism's signs and symptoms, with an acceptable safety burden," the company said.
Chief Executive Joseph Belanoff said the drug's combination of efficacy and safety gives it the potential to become the standard of care for the medical treatment of patients with hypercortisolism.
Cortisol, which is sometimes called the stress hormone, helps to maintain blood pressure, regulate blood sugar, reduce inflammation and convert food into energy. In excessive amounts cortisol can cause health problems including high blood pressure, obesity, elevated blood sugar, severe fatigue and behavior disturbances.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 30, 2024 17:48 ET (22:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。